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Introduction
Estrogen receptors (ERs) are members of the nuclear
receptor (NR) superfamily that mediate the pleiotropic
effects of the steroid hormone estrogen in a diverse range
of developmental and physiological processes [1].
Although estrogens are important physiological regulators
in the reproductive system, in bone metabolism, and in the
maintenance of the cardiovascular and central nervous
systems, they have also been associated pathologically
with an increased risk for breast and endometrial cancer
[2–5]. Consequently, ERs have been found to be essential
in the initiation and development of most of these cancers.
Current endocrine therapies for ER-positive breast
cancers are primarily designed to target either estrogen or
ER levels and/or activity. Use of a partial antiestrogen,
tamoxifen, in the management of early-stage breast cancer
has clearly demonstrated an increase in both disease-free
and overall survival. In addition, recent studies demon-
strate that tamoxifen can be used as a chemopreventive
agent for hormone-dependent breast cancer. The major
concerns of long-term therapy with tamoxifen are its
uterotropic effects, which result in an increased risk for
endometrial cancer, and the acquired clinical resistance to
tamoxifen. This has led to the active pursuit of better
selective ER modulators (SERMs) that display the optimal
agonistic or antagonistic activities in various estrogen
target tissues.
In this article we review the emerging studies of ER action
that reveal the roles of a wide spectrum of receptor coreg-
ulators and their interaction with other cellular signaling
pathways. An understanding of the molecular factors that
modulate the activity of the estrogen-signaling network
provides insight into the mechanism by which SERMs
exert their tissue-specific effects. The identification of
factors that are responsible for such effects is enabling
the development of new ways to overcome resistance to
endocrine therapy.
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Abstract
Estrogen receptor (ER) has a crucial role in normal breast development and is expressed in the most
common breast cancer subtypes. Importantly, its expression is very highly predictive for response to
endocrine therapy. Current endocrine therapies for ER-positive breast cancers target ER function at
multiple levels. These include targeting the level of estrogen, blocking estrogen action at the ER, and
decreasing ER levels. However, the ultimate effectiveness of therapy is limited by either intrinsic or
acquired resistance. Identifying the factors and pathways responsible for sensitivity and resistance
remains a challenge in improving the treatment of breast cancer. With a better understanding of
coordinated action of ER, its coregulatory factors, and the influence of other intracellular signaling
cascades, improvements in breast cancer therapy are emerging.
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ERα α and ERβ β: structure
Two mammalian ERs have been identified, ERα and ERβ,
encoded by independent genes [6–8]. ERα was cloned
nearly two decades ago and was believed for many years
to be the only ER. The subsequent cloning of ERβ
increased the complexity of estrogen signaling. Both ER
isoforms share modular structures characteristic of the NR
superfamily, which include six functional domains (Fig.1)
[9]. The most conserved domain is the central DNA-
binding domain (DBD, region C), followed by the ligand-
binding domain (LBD, region E). The LBD also contains a
dimerization surface and a ligand-dependent activation
function 2 (AF-2). AF-2 undergoes a marked conforma-
tional change in the presence of different ligands, and
determines the subsequent binding of coactivators or
corepressors. Activation function 1 (AF-1), located in the
N-terminal A/B domain, is regulated by growth factors and
its activity depends on the cellular and promoter context.
AF-1 and AF-2 act synergistically to attain maximal recep-
tor transcriptional activity. Although both ERα and ERβ
display similar binding affinities for 17β-estradiol (E2), they
have different roles in the regulation of gene expression.
The low level of conservation within the A/B domains of
ERα and ERβ might be responsible for these functional
differences between the two receptors by interacting with
unique sets of transcription factors.
ER exerts its transcriptional effects through both direct
and indirect binding to specific DNA sites, termed estro-
gen response elements (EREs), located in the promoter
and/or enhancer regions of target genes [10]. The con-
sensus EREs consist of two inverted, palindromic half-
sites of PuGGTCA motifs. ER can bind EREs as ERα or
ERβ homodimers or as ERαβ heterodimers. The affinity
and the specificity of ER binding are determined by both
the sequence and spatial organization of the motifs
[11,12]. In addition to signaling directly through EREs, ER
can act more as a coactivator to modulate transcriptional
responses via interactions with other classes of DNA-
bound transcription factors, such as AP-1 or SP-1
[13,14]. These different modes of ER action have been
suggested to have an important role in determining differ-
ential responses to various ER ligands.
Ligand-dependent ER-mediated transcription:
coregulators
It is now recognized that ER-mediated transcription is a
highly complex process involving a multitude of coregula-
tory factors and ‘cross-talk’ between distinct signaling
pathways (Fig.2) (reviewed in [15]). The existence of inter-
mediary factors in the ER action was suggested by several
observations, including the tissue-specific activities of
tamoxifen and the cross-squelching observed between
cotransfected receptors in transcription assays. By follow-
ing this lead and using biochemical approaches as well as
yeast two-hybrid screens, over 30 coregulatory molecules
have been identified. For simplicity they can be broadly
divided into coactivators, which augment the activity of
receptors, and corepressors, which mediate the repres-
sive effects of receptors (reviewed in [16]).
Transcriptional activation involves alterations in chromatin
structure mediated by ATP-dependent chromatin-remodel-
ing enzymes in conjunction with factors that contain
histone acetyltransferase (HAT) activity [17]. Consistent
with this concept is the observation that ER recruits
BRG1, a mammalian homologue of a component of the
SWI/SNF chromatin remodeling complex, to EREs in a
cooperative manner with HATs [18]. Further, many ER
coactivators possess intrinsic HAT activities, including
CBP/p300, p/CAF, and TAFII250 [19–21]. Other coacti-
vators such as the p160 coactivators facilitate ER tran-
scription by serving as platforms to recruit HATs and
protein methyltransferases.
There are three members of the p160 family of coactiva-
tors, NCoA-1 (SRC-1) [22], NCoA-2 (TIF2, GRIP1)
[23,24], and NCoA-3 (AIB1, ACTR, RAC3, p/CIP,
Figure 1
Schematic diagram of the two human estrogen receptors, ERα and ERβ. Both receptors consist of six functional domains, including the DNA-
binding domain (DBD), the ligand-binding domain (LBD), the ligand-independent activation function AF-1, and the ligand-dependent activation
function AF-2. The percentage identity between the two receptors is indicated.41
TRAM-1) [25–30], which share extensive structural
homology. They all contain a bHLH–PAS (basic
helix–loop–helix–Per/ARNT/Sim) domain in the amino-ter-
minus. Although this domain mediates DNA binding in
other factors that contain it, no evidence of direct contact
of the p160 coactivators with DNA has been demon-
strated. In the central region of the p160 proteins there is
a domain that mediates the interaction of p160 coactiva-
tors to the LBD of agonist-bound ER through several short
helical motifs with the sequence LXXLL [31]. The C-termi-
nal region of the p160 proteins mediates interaction with
other factors with a role in ER signaling including CBP
(CREB-binding protein), p300 and arginine methyltrans-
ferase 1 (CARM-1) [32].
In spite of significant sequence homology between p160
members, several lines of evidence suggest that in addi-
tion to some degree of functional redundancy they have
unique functions as well. Although all three p160 coactiva-
tors are widely expressed at low levels in a number of
tissues, they exhibit high levels of expression in selective
tissues. NCoA-1 has relatively high levels of expression in
the brain and pituitary [33], whereas NCoA-2 has the
highest levels in the testis [23], and NCoA-3 in the thyroid
gland, thymus, kidney, lung, and skin [34]. Further, the
levels of expression of these coactivators are hormonally
regulated. For example, thyroid hormone upregulates
NCoA-1 mRNA levels in the anterior pituitary, whereas E2
downregulates its expression [33]. Both the mRNA and
protein levels of NCoA-3 can be suppressed by E2, and
this repression is reversed by antiestrogens or all-trans
retinoic acid [35].
More evidence of their distinct physiological functions
comes from knockout mouse models. Deletion of the gene
encoding NCoA-1 in mice resulted in only mild defects in
hormone target tissues such as uterus, mammary gland,
testis, and prostate. These tissues exhibit decreased
growth and development in response to steroid hormones
in the absence of NCoA-1 [36]. In addition, disruption of
NCoA-1 causes a delay in Purkinje cell development and
the maturation of the cerebellum leading to moderate
motor dysfunction in adulthood [37]. Genetic deletion of
NCoA-3 leads to a different spectrum of phenotypes,
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Figure 2
ER regulation by a variety of signals. Growth factors such as epidermal growth factor, insulin-like growth factor-1, insulin, and transforming growth
factor-β bind to and activate their receptors, which in turn activate the RAS–RAF–ERK and the phosphoinositide 3-kinase (PI3K) pathways; the
activated kinases then phosphorylate and activate ER. Other extracellular stimuli such as dopamine and cyclic AMP bind G-protein-coupled
receptors and activate adenylyl cyclase (AC) and protein kinase A (PKA), which subsequently phosphorylate and activate ER. ER can also interact
directly with components of the cytosolic signaling molecules, including the regulatory subunit of PI3K, leading to the activation of the
serine/threonine kinase Akt. In the nucleus, hormone binding results in receptor dimerization and recruitment of coactivators or corepressors
depending on the bound ligand, leading to transcriptional activation or repression. ERE, estrogen response element; MEK, MAP kinase/ERK
kinase; SERM, selective estrogen receptor modulator.42
including stunted somatic growth, delayed puberty, abnor-
mal reproductive function and retarded mammary ductal
growth [34,38]. The more severe defects observed in the
mammary gland in these mice suggests that NCoA-3
might have a more pronounced role in regulating
mammary gland functions.
In addition to the chromatin remodeling complexes and
the p160 family, a wide spectrum of coactivators has been
found to interact with ER. These include DRIP205/
TRAP220/PBP, a component of the DRIP/TRAP mediator
complex [39–41], PGC-1, a tissue- and promoter-specific
PPARγ-coactivator-1 [42,43], SNURF, a small nuclear
C(3)HC(4) finger protein [44], PELP1, a proline-, glutamic
acid-, leucine-rich protein 1 [45], and NCoA-7
(ERAP140), a structurally distinct coactivator [46]. With
the exception of NCoA-7, most of these coactivators
possess the canonical LXXLL motif that mediates their
agonist-induced interaction with the ER LBD. The
common mode of interaction of a large number of coactiva-
tors involving the LXXLL motif with most of the nuclear
receptor raises the problem of a potential lack of specificity.
One solution to this problem might be that sequences flank-
ing the core motif can determine receptor selectivity, as
suggested by phage display experiments [47].
In contrast to these factors that all bind to the ER LBD,
some coactivators, such as the steroid receptor RNA acti-
vator SRA and the RNA helicases p68/p72, interact with
and regulate the AF-1 domain of ER [48–50]. GT198, a
tissue-specific and kinase-regulated coactivator, interacts
with the ER DNA-binding domain. GT198 differs from
other coactivators in that it regulates basal receptor activ-
ity and hormone sensitivity [51]. Some ER-interacting pro-
teins have other distinct biological functions. Cyclin D1, a
protein frequently overexpressed in breast cancer, has
been shown to activate unliganded ER through recruiting
p160 coactivators and p/CAF [52–55]. The calcium-
binding protein calmodulin and the activating enzyme of
NEDD8, Uba3, both regulate ER activity by modulating the
steady-state level of the receptor [56,57]. The Sma and
MAD-related protein 3 (SMAD3) interacts with ER, allow-
ing cross-talk between the estrogen and the transforming
growth factor-β signaling pathways [58]. Similarly, MNAR,
a modulator of nongenomic activity of ER, modulates ER
interaction with members of the Src family of tyrosine
kinases, leading to stimulation of their enzymatic activity,
which in turn enhances ER transcriptional activity [59].
Opposing the mechanism by which coactivators effect
transcriptional activation by modulating chromatin state,
NR corepressors negatively regulate transcription via their
recruitment of histone deacetylases (HDACs). The best
characterized corepressors are the structurally related
proteins N-CoR and SMRT, which interact with the repres-
sive form of nuclear receptors such as the unliganded
retinoic acid and thyroid hormone receptors [60,61]. In
the case of ER, both N-CoR and SMRT bind ER in the
presence of antagonists such as tamoxifen and are
recruited to the promoter of target genes [62–65]. Other
proteins act to repress ER-mediated transcription by dis-
tinct mechanisms [66–69]. Examples include the ER-spe-
cific corepressor REA, as well as the orphan receptors
SHP and DAX-1, which act by competing with the p160
coactivators for binding agonist-bound ER.
Structure of the ER LBD
Complementing the molecular studies of ER regulation,
structural analyses of the ER LBD have shed further light
on our understanding of ER function, in particular its inter-
action with coactivators and the structural basis of recep-
tor agonism and antagonism. A wide repertoire of
structurally and chemically distinct compounds bind to ER.
Some of these compounds, such as the natural ligand E2
and the synthetic diethylstilbestrol (DES), act as receptor
agonists, whereas others compete for E2 binding and act
as antagonists. Structural studies of the ER LBD have
established that ER ligands have a profound effect on the
receptor structure. The structure of ER LBD exhibits a
α-helical sandwich topology distinctive of NR LBDs: it
consists of 12 helices (H1–H12) arranged in three anti-
parallel layers separated by β-sheets [70]. Although the
overall conformation of the ER LBD is quite similar in the
presence of various compounds, the carboxy-terminal
transactivation domain (AF-2, H12) is highly sensitive to
the nature of the bound ligand.
Structures of ER LBD in complex with E2, DES, the
SERMs raloxifene and tamoxifen, and the pure antiestro-
gen ICI 164,384, an analogue of fulvestrant (ICI 182,780),
have been determined [71–74]. ER agonists induce a
major conformational change in the receptor: H12 is repo-
sitioned and aligned over the ligand-binding cavity, result-
ing in a specific binding site for the consensus LXXLL
motif of the coactivators [75,76]. However, binding of
raloxifene or tamoxifen sterically hinders the H12 position-
ing and prevents the formation of the coactivator-binding
surface [71–73]. The pure antiestrogen ICI 164,384
elicits an unusual organization of the LBD [74]. ICI
164,384 is a 7α-alkylamide analog of E2 and its protrud-
ing 7α sidechain substituent sterically prevents H12 from
aligning over the ligand-binding cavity; further, the posi-
tioning of the terminal amide portion of the sidechain
occludes H12 from adopting its alternative position over
the coactivator-binding cleft. Consequently, ICI 164,384
seems to completely abolish H12 association with the
LBD, which might be crucial for generating its full antago-
nist effect. However, our increased understanding of the
structural changes induced by various ER ligands has yet
to allow the design of a SERM with an optimal balance
between the agonistic and antagonistic properties in the
desired target tissues.
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Ligand-independent ER activation: cross-talk
with other signaling pathways
ER regulation is not limited to direct ligand binding,
because it can also be modulated by several other path-
ways. These include the epidermal growth factor (EGF)
and insulin-like growth factor-1 (IGF1) mitogenic pathways
and the second messengers cyclic AMP (cAMP) and
dopamine (reviewed in [77–79]) (Fig.2). Activation of
these pathways influences ER transcriptional activity either
by targeting the receptor directly or by regulating the activ-
ities of receptor coregulators. For instance, activation of
epidermal growth factor receptor (EGFR) by EGF leads to
phosphorylation of the Ser118 residue in the ERα AF-1
domain by p44/42 mitogen-activated protein kinase
(MAPK), which in turn recruits the coactivator p68/p72
and activates target gene transcription in a ligand-inde-
pendent manner [80,81]. In contrast, ligand-dependent
S118 phosphorylation is mediated through the associa-
tion of ERα with TFIIH and the cyclin-dependent kinase
CDK7 [82,83]. In addition, the activation of protein
kinase A (PKA) by cAMP results in ER phosphorylation
and increased transactivation of an ERE-containing
reporter [84,85]. One report suggests that Ser236 phos-
phorylation by PKA inhibits ER dimerization, and this inhi-
bition can be reversed by E2 [86].
ER coregulators are also targets of many of the same sig-
naling pathways that affect ER directly. MAPK can phos-
phorylate p160 coactivators NCoA-1 and NCoA-3, and
can enhance their transcriptional activities partly by facili-
tating their interaction with CBP/p300 [87,88]. CBP itself
can also be phosphorylated and activated through the
p42/44 MAPK cascade [89–91]. Phosphorylation of CBP
by both MAPK [92] and cyclin-dependent kinases (CDKs)
leads to an upregulation of its HAT activity [93].
Although it has been well established that growth factors
can modulate ER transcriptional activity, the observation
that activated ER can transmit signals that modulate these
signal transduction pathways has been more difficult to
dissect. Studies suggest that E2-bound ER can activate
the extracellular signal-regulated kinase (ERK) or the
phosphoinositide 3-kinase (PI3K), leading to the activation
of downstream signaling molecules [94,95]. The existence
of transcription-independent ER functions increases the
potential diversity of ER signaling. It remains to be deter-
mined which physiological and pathological activities of
ER are dependent on its non-genomic activities.
ER and breast cancer
An important role for ER in breast cancer has been known
for almost 30 years [96]. Although both ERα and ERβ
have been implicated, the role of ERβ in breast cancer
remains elusive (reviewed in [97]). ERα is expressed in a
subset of normal breast epithelial cells, and ERα-contain-
ing epithelial cells do not normally proliferate in response
to estrogen [98]. In this view, estrogen stimulates the
normal mammary epithelium to secrete growth factors that
stimulate neighboring ER-negative epithelial cells to prolif-
erate in a paracrine fashion. In contrast to the normal
breast, most pre-malignant breast lesions express high
levels of ERα, and ERα-expressing breast cancer cells are
hormone-dependent and undergo regression when estro-
gen is removed (reviewed in [99]). Thus, ERα is a well-
established predictive marker of hormone sensitivity in
breast cancer as well as a positive prognostic marker.
Further, the presence of ERα in breast cancer at the time
of diagnosis is an indication for endocrine therapy. In the
advanced disease setting, many patients with ERα-posi-
tive breast tumors will respond favorably, at least initially,
to endocrine therapies.
Because ER-positive breast cancer is estrogen-depen-
dent, reducing estrogen levels or altering the activity of the
receptor can induce these cancers to regress. Oophorec-
tomy remains an option for premenopausal women with
ER-positive tumors; however, medical rather than surgical
approaches are more widely used. Current approaches
designed to reduce levels of circulating estrogen include
selective aromatase inhibitors and luteinizing-hormone-
releasing hormone (LHRH) agonists. Drugs that target ER
fall into two major classes. These include SERMs such as
tamoxifen and the pure antiestrogens such as fulvestrant,
which reduce ER concentrations.
Menopausal status has an important role in determining
therapy (Fig.3). Small, randomized trials in premenopausal
women have suggested that tamoxifen brings treatment
benefits similar to those with oophorectomy. Moreover,
tamoxifen can be used effectively as a second-line
endocrine therapy after oophorectomy, and vice versa
[100,101]. In postmenopausal women, the primary source
of estrogen is not from ovarian synthesis but from the con-
version of androstenedione to estrone and estradiol in the
peripheral tissues including the breast. Aromatase
inhibitors block the final step in the conversion of andro-
gen to estrogen and have been widely used in the treat-
ment of postmenopausal women with advanced breast
cancer (reviewed in [102,103]).
The current aromatase inhibitors used are the third-gener-
ation inhibitors and are much better tolerated than their
nonselective predecessors. They can be divided into non-
steroidal (anastrazole and letrozole) and steroidal
(exemestane) inhibitors (Fig.4). Anastrazole was the first
aromatase inhibitor to be approved for second-line treat-
ment of advanced breast cancer in postmenopausal
women; letrozole and exemestane were later found to
have similar efficacy [104–107]. And recently, both anas-
trazole and letrozole were shown to have a higher efficacy
than tamoxifen as first-line therapy for patients with
advanced ER-positive tumors [108,109]. The efficacy of
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aromatase inhibitors as adjuvant therapy is currently being
tested in the ATAC (Arimidex, Tamoxifen, Alone or in Com-
bination) trial [110].
Tamoxifen and SERMs
The concept of manipulating the endocrine system in the
treatment of breast cancer was developed more than
100 years ago, after the first demonstration that oophorec-
tomy could lead to regression of the disease in pre-
menopausal women with metastatic breast cancer [111].
Subsequently, this concept has led to the development of
effective and relatively safe drugs, such as tamoxifen
[112,113].
Tamoxifen is a first-generation non-steroidal SERM and is
currently the most frequently prescribed drug for the treat-
ment of all stages of breast cancer. Tamoxifen was
approved by the Food and Drug Administration (FDA) in
1977 for the treatment of women with advanced breast
cancer, in 1986 for adjuvant treatment of primary breast
cancer, and later in 1990 for adjuvant therapy in pre-
menopausal and postmenopausal women with node-nega-
tive disease (reviewed in [113,114]). For women with
ER-positive breast tumors, tamoxifen results in a 50%
annual reduction in the recurrence rate and a 28% annual
reduction in the death rate [115,116]. Women with
metastatic disease who have ER-positive tumors also
benefit from treatment with tamoxifen [117]. In addition,
findings that tamoxifen could reduce the incidence of con-
tralateral breast cancer led to breast cancer prevention
trials [118]. The Breast Cancer Prevention Trial (BCRT)
demonstrated that tamoxifen can be used as a preventive
therapy because it reduced the incidence of ER-positive
breast cancer by about 50% [119,120]. The results of the
International Breast Cancer Intervention Study (IBIS-1)
also showed a more than 30% reduction in the risk for
breast cancer in tamoxifen-treated group compared with
placebo. There was, however, a significantly higher rate of
venous thromboembolic events in the tamoxifen group,
raising the concern of overall risk:benefit ratio for the pro-
phylactic use of tamoxifen [121].
The success of tamoxifen is based on a balance between
its agonistic and antagonistic activities. Tamoxifen is an
antagonist in the breast, whereas it has agonist effects on
bone, serum lipid profile, and the cardiovascular system
[122–126]. The antiestrogenic activity of tamoxifen in the
breast is mediated by its competitive inhibition of estrogen
binding to ER and the recruitment of corepessors rather
than coactivators to target promoters [127,128]. Although
the efficacy of tamoxifen in treating breast cancer has
been attributed to both its cytostatic and cytotoxic effects
[129–133], the critical targets remain to be defined.
A serious adverse effect of tamoxifen is an increased inci-
dence of endometrial cancer due to its undesirable ago-
nistic activity in the uterus [134,135]. Compelling
evidence suggests that the estrogenic effect of tamoxifen
is highly dependent on the tissue, the cell, and the pro-
moter context. Work from several groups has implicated
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Figure 3
Therapy for women with ER-positive breast tumors.45
various coregulators as the mediators of these cell-type
and promoter-specific effects. In one model, tamoxifen
inhibits the activation of the ER AF-2 domain but does not
inhibit AF-1 activity, allowing AF-1 to recruit coactivators
such as steroid hormone receptor coactivator-1 (SRC-1)
and p68 [49,136,137]. In contrast, the expression level of
corepressors such as SMRT and N-CoR has been sug-
gested to have a role in the antagonist activity of tamox-
ifen: blocking N-CoR or SMRT expression might convert
tamoxifen into an agonist [138]. In mouse embryonic
fibroblasts (MEFs) from N-CoR–/– animals, tamoxifen func-
tions as a full agonist on ER-regulated transcription, and
the introduction of N-CoR expression in these MEFs
reverses this effect [139].
In addition to the level of expression, the level of corepres-
sor binding can influence SERM effects on ER activity
[64]. However, when Morrison and co-workers inhibited
the N-CoR activity by a dominant-negative N-CoR con-
struct in MCF-7 cells, the transcriptional activity of ER was
not altered by treatment with tamoxifen. Correspondingly,
the histone acetylation levels in the promoters of the
endogenous estrogen-responsive genes were unchanged
in cells expressing the dominant-negative N-CoR con-
struct, regardless of ligand. In vitro cell proliferation and in
vivo tumor growth were also unaffected in these cells.
These results suggest that corepressors other than
N-CoR might be involved in the ability of tamoxifen to
repress estrogen-responsive transcription and tumor
growth [140]. Nevertheless, compelling evidence sup-
ports the notion that binding to selective coregulatory
factors on a specific target gene promoter in a given
tissue or cell type determines the agonistic/antagonistic
activity of tamoxifen. In certain tissues such as the uterus,
in which the AF-1 activity is more significant, the agonistic
activity of tamoxifen is predominant [141]. Recent work
has demonstrated that, in endometrial cancer cells, tamox-
ifen acts like estrogen by stimulating the recruitment of
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Figure 4
Chemical structures of the three FDA-approved selective estrogen receptor modulators (SERMs), the pure antiestrogen Faslodex, and the
aromatase inhibitors (AIs). The SERMs include the triphenylethylenes tamoxifen and toremifene, and the benzothiophene raloxifene. AIs include the
nonsteroidal anastrazole and letrozole, and the steroidal exemestane.46
coactivators to the non-classical target gene promoters,
and this requires a higher level of p160 coactivators
[128].
The undesirable estrogenic activity of tamoxifen in the
uterus has fueled the search for better SERMs. Two addi-
tional SERMs have been approved by the FDA for clinical
use in the USA: toremifen for the treatment of advanced
breast cancer and raloxifene for the prevention and treat-
ment of postmenopausal osteoporosis (Fig.4). Like tamox-
ifen, toremifene is a derivative of triphenylethylene and
thus has very similar efficacy and side-effect profiles to
those of tamoxifen, and exhibits cross-resistance with
tamoxifen [142–144]. Raloxifene is a nonsteroidal ben-
zothiophene and has a somewhat different profile of activi-
ties. When raloxifene was tested in the Multiple Outcomes
Raloxifene Evaluation (MORE) trial for its effect on bone
mineral density and vertebral fracture incidence in post-
menopauseal women with osteoporosis, it was found to
have clear benefits in decreasing the risk for vertebral frac-
tures and in increasing bone density. Moreover, raloxifene
was reported to reduce the risk for invasive breast cancer
by 72% and the risk for ER-positive breast cancer by 84%
[145]. This, together with the observation that raloxifene
does not increase the risk for endometrial cancer, raised
the question whether raloxifene would have advantages
over tamoxifen as a chemopreventive agent in women at
increased risk for breast cancer. The ongoing STAR
(Study of Tamoxifen And Raloxifene) trial should resolve
this issue [146].
In addition to a role for coregulators in determining the
spectrum of SERM activity, other mechanisms are proba-
bly important (reviewed in [147–150]). For example, ERβ
is expressed only in certain target tissues, and its
responses to various ligands are distinct from those of
ERα [151–153]. Thus, the biological activities of SERMs
are determined by a multitude of mechanisms. It is hoped
that an understanding of these mechanisms in detail will
lead to the development of new SERMs with the desired
clinical profile.
Tamoxifen resistance
The efficacy of tamoxifen in many patients with breast
cancer is limited by a couple of factors. First, only
60–70% of the breast tumors are ER-positive, and the
anti-tumor activity of tamoxifen is observed exclusively in
tumors that express ER. Second, almost all patients with
advanced breast cancer who initially respond to tamoxifen
therapy will eventually develop resistance to the therapy.
Potential genetic or epigenetic changes within the tumor
that might contribute to tamoxifen resistance include the
following: altered ER expression; hypersensitivity of ER to
low levels of circulating estrogen due to ER mutations or
variants that lead to constitutively transcriptionally active
ER; altered levels and/or activities of coactivators and
corepressors that lead to ER activation, rather than inhibi-
tion, by tamoxifen; and ligand-independent ER activity
stimulated by aberrant expression of growth factors.
Although loss of ER expression has been reported in a
few cases of tamoxifen resistance [154], most of the
acquired resistance is not due to alteration in the ER
status, and many of these tumors respond to second-line
endocrine therapies.
Differences in mechanisms by which tamoxifen and other
endocrine therapies affect ER function might define pat-
terns of cross-resistance between tamoxifen and the
second-line therapy. Cross-resistance between triphenyl-
ethylenes, for instance tamoxifen and toremifene, has been
clearly demonstrated in breast cancer patients. This is also
true of tamoxifen and raloxifene. In contrast, the pure antie-
strogen fulvestrant can induce responses in patients who
have failed to respond to tamoxifen. Aromatase inhibitors
have also produced significant responses as second-line
therapies after antiestrogens.
We have reviewed above that recruitment of coactivators
or corepressors to ER has a role in determining the switch
between receptor activation and repression, and the coor-
dinated action of ligand, receptor, and coregulators con-
tributes to distinct patterns of gene expression in
biological settings. Cumulative evidence suggests that
intricate modulation of the receptor:coregulator ratio in
distinct cells and tissues determines their response or
resistance to endocrine therapy. The p160 coactivator,
AIB1 (for ‘amplified in breast cancer’), was identified on
the basis of its frequent amplification in breast cancer
[25]. Overexpression of AIB1 mRNA and protein has been
revealed in more than 60% and roughly 10% of the breast
tumors, respectively [155,156]. High levels of both AIB1
and HER-2 protein in breast tumors have been recently
associated with tamoxifen resistance. A potential mecha-
nism of this resistance involves activation of the MAPK
cascade resulting from increased signaling from HER-2,
which in turn activates AIB1, and the high level of AIB1-
mediated ER activity increases the agonistic activity of
tamoxifen [157]. Conversely, low mRNA levels of the core-
pressor N-CoR have been associated with resistance to
tamoxifen [158]. Identifying aberrant coregulators will
assist in designing future therapeutic applications to
improve the efficacy of the current endocrine therapy. It
remains a challenge to dissect the regulation of a specific
coregulator in a given cell or tissue type in response to
SERMs and to target the factors without having detrimen-
tal effects because these factors are also involved in medi-
ating responses from a variety of signaling pathways.
Apart from hormonal therapies that directly target estro-
gen–ER signaling, inhibitors of growth factor activity have
attracted increasing interest in the treatment of breast
cancer. EGFR and ErbB-2/HER-2/neu are examples of
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growth factor signaling molecules that are being targeted
for breast cancer. Overexpression of EGFR or expression
of a truncated and constitutively active form of EGFR is
found in some breast cancers [159–161]. More impor-
tantly, HER-2 amplification is found in about 25% of
breast cancers and is correlated with poor disease-free
survival and resistance to chemotherapy and endocrine
therapy (reviewed in [162]).
Strategies to target EGFR and ErbB-2/HER-2/neu include
antireceptor antibodies, tyrosine kinase inhibitors,
ligand–toxin conjugates, and receptor antisense mole-
cules (reviewed in [163]). The tyrosine kinase inhibitor
Iressa (ZD 1839, gefitinib) was developed mainly for the
treatment of advanced lung cancers but has been shown
in phase I/II trials to have potential benefits in other solid
tumors, including breast cancer. Treatment with Iressa can
inhibit growth of breast cancer cell lines in vitro that are
resistant to tamoxifen and fulvestrant. Moreover, when
used concurrently with either of the antiestrogens, Iressa
prevented the development of resistance [164].
Trastuzumab (Herceptin), a humanized monoclonal anti-
body directed against the extracellular domain of the
HER-2 protein, is the first HER-2-directed therapy that has
gained approval from the US FDA for the treatment of
patients with metastatic breast cancer [165]. Several
phase II trials have indicated that trastuzumab has syner-
gistic or additive effects in combination with chemothera-
pies and hormonal agents. In vitro studies have shown
that treatment with trastuzumab in HER-2-overexpressing
breast cancer cells can restore cell sensitivity to both
estrogen and tamoxifen [163].
Other nuclear receptor-targeted therapies
In addition to ER, progesterone receptor is targeted in the
treatment of advanced receptor-positive breast cancer.
However, because of their side-effect profile, progestins
are in general now used as third-line or fourth-line therapy
[166]. Other agents currently under development for the
prevention and treatment of breast cancer include the
ligands of other nuclear receptors. Retinoids, ligands for
the retinoic acid receptors (RARs and RXRs), have been
shown to inhibit cell proliferation in breast cancer cells
[167–171]. Other nuclear receptor ligands that have been
shown to exhibit inhibitory effects on breast cancer
include those for PPARγ and VDR (vitamin D receptor)
(reviewed in [172–174]). Although this is an area of active
investigation, none of these compounds has yet made it to
the clinic.
Conclusions and future perspectives
The ER signaling hierarchy is far from isolated from other
cellular signaling cascades. It integrates multiple signals
from both hormonal ligands and other extracellular and
intracellular stimuli in coordination with an array of cofac-
tor complexes, and regulates both physiological and
pathological processes. The clinical limitation of the first-
generation SERM, tamoxifen, has fueled an intense search
for newer and better SERMs. The ultimate goal of the
SERM research is to find a molecule that has all the bene-
fits of estrogen, none of its adverse effects, and offers pro-
tection against breast cancer. To achieve this goal, a
better understanding is needed of how the orchestrated
action of SERM, receptor, and coregulators contribute to
distinct patterns of gene expression. Multiple studies have
supported the hypothesis that intricate modulation of the
receptor–coregulator interaction on a specific target gene
promoter in a given tissue, cell, or tumor context can
dictate the degree and direction of SERM action.
Dissecting the interrelationship between ER and its coreg-
ulators may open the door for the rational design of novel
therapeutics. The cellular dynamics of these cofactor com-
plexes are beginning to be elucidated with assays such as
chromatin immunoprecipitation (ChIP) and real-time
imaging techniques. An understanding of how the
program of ER-regulated transcription is dysregulated in
breast cancer and how it changes with the development
of resistance to endocrine therapy will lead to improved
strategies for the use of existing endocrine therapies and
for the development of new and more effective agents for
the prevention and treatment of breast cancer.
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